Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

NCT05132504 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: Pembrolizumab
DRUG: Folfirinox

Sponsor

Baylor College of Medicine

Collaborators

[object Object]
[object Object]